49 results about "Mapk signaling pathway" patented technology

The invention discloses the use of hordenine in the preparation of drugs for treating pituitary tumors, and relates to the technical field of biopharmaceuticals. Specifically, in this application, the inventors have discovered that hordenine can inhibit TLR4 / NF-κB / The MAPK signaling pathway helps to treat prolactinoma and adrenocorticotropic adenoma to play a drug effect, and solves the plight of drug shortage for patients with prolactinoma and adrenocorticotropic adenoma.

The invention discloses the application of amygdalin in the preparation of anti-inflammatory drugs for knee osteoarthritis. In an inflammatory state, AMD regulates the expression of Dnmt3b by inhibiting the p38 / MAPK signaling pathway, thereby delaying the degeneration of chondrocytes. It was verified in vivo that AMD regulates the metabolism of chondrocytes by regulating the p38 / MAPK / Dnmt3b signaling pathway, thereby delaying the degeneration of OA. Therefore, AMD has a good application prospect in the clinical treatment of osteoarthritis. Because the existing anti-inflammatory and analgesic drugs often have gastrointestinal tract reactions, allergic reactions and kidney damage, the present invention can well control side effects within the range of effective doses without affecting the enhancement of the anti-inflammatory ability of chondrocytes.

The invention discloses application of Chinese softshell turtle Cathelicidin-Ps-CATH4 peptide in preparation of an anti-inflammatory drug, and belongs to the technical field of biomedicine. Ps-CATH4 is linear peptide, and contains 32 amino acid residues; RT-PCR displays that the peptide has an inhibition effect on expression of critical inflammatory factors induced by lipopolysaccharide and an inducible NO synthase gene; and on the protein level, the peptide has a negative regulation effect on LPS-induced inflammatory factors and NO release, has an ascending effect on expression of inflammatory factors, and is mainly used for inhibiting release of the inflammatory factors by inhibiting activation of a TLR4 acceptor and a downstream MAPK signal channel. The peptide is simple in structure, does not contain a disulfide bond or a cyclic structure; chemical synthesis and genetic engineering preparation are facilitated; the primary medicinal evaluation shows low cytotoxicity and hemolytic activity; and the peptide is good in stability on salt, blood serum, temperature and time, and is applied to preparation of the anti-inflammatory drug.

The invention provides application of polyguluronate sulfate to anti-hepatitis B virus medicine preparation. Experiments prove that the polyguluronate sulfate is capable of well inhibiting expression of an HBV (hepatitis B virus) HBsAg (hepatitis B surface antigen) and an HBV HBeAg (hepatitis Be antigen) in a hepatocellular carcinoma cell line HepG2.2.15, remarkably inhibiting expression of HBV-S mRNA (messenger ribonucleic acid) in the hepatocellular carcinoma cell line HepG2.2.15, enhancing generation and secretion of anti-virus immunity-associated IFN (interferon)-beta in cells and activating NF (nuclear factor)-kappa B and MAPK (mitogen-activated protein kinase) signal pathways. The polyguluronate sulfate which is a marine sulfated polysaccharide compound has the advantages of rich resources, low cost, high safety and the like, and is obviously superior to positive control drug lamivudine in anti-HBV effect, thereby being promising in application prospect of anti-hepatitis B virus medicine preparation.

The invention relates to the application of RPS9 protein in the prediction of good response to superovulation in cynomolgus monkeys, belonging to the technical field of superovulation. The method of proteomics is used to analyze the first day of superovulation success group and the fifth day of superovulation success group. , Superovulation failure group on day 1 and superovulation failure group on day 5 for bioinformatics analysis to obtain the differential protein among the groups. From the study of protein level, the changes of protein expression revealed in the blood of superovulated monkeys were explored. In superovulation in cynomolgus monkeys, RPS9 protein was expressed on day 5 in the superovulation success group, but not in the superovulation failure group on day 5. It is suggested that the down-regulation of PRS9 expression in the superovulation failure group affects the activation of MAPK signaling pathway and NK-κB pathway, thereby leading to cell apoptosis, cell cycle arrest and inhibition of proliferation. The down-regulation of PRS9 expression may lead to the activation of p53, resulting in the inhibition of cell proliferation, thereby affecting the formation of follicles and leading to the failure of superovulation response. Therefore, RPS9 protein has become a new molecule to predict the good response to superovulation in cynomolgus monkeys, and has practical application value.

An application of eriocalyxin B in preparing the medicines for treating acute leukemia and Burkitt's lymphoma is disclosed.